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Abstract 
Sesquiterpenes are C15 isoprenoids with utility as fragrances, flavours, pharmaceuticals, and potential 
biofuels. Microbial fermentation is being examined as a competitive approach for bulk production of 
these compounds. Competition for carbon allocation between synthesis of endogenous sterols and 
production of the introduced sesquiterpene limits yields. Achieving balance between endogenous 
sterols and heterologous sesquiterpenes is therefore required to achieve economical yields. In the 
current study, the yeast Saccharomyces cerevisiae was used to produce the acyclic sesquiterpene 
alcohol, trans-nerolidol. Nerolidol production was first improved by enhancing the upstream 
mevalonate pathway for the synthesis of the precursor farnesyl pyrophosphate (FPP). However, 
excess FPP was partially directed towards squalene by squalene synthase (Erg9p), resulting in 
squalene accumulation to 1 % biomass; moreover, the specific growth rate declined. In order to re-
direct carbon away from sterol production and towards the desired heterologous sesquiterpene, a 
novel protein destabilisation approach was developed for Erg9p. It was shown that Erg9p is located 
on endoplasmic reticulum and lipid droplets through a C-terminal ER-targeted transmembrane peptide. 
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A PEST (rich in Pro, Glu/Asp, Ser, and Thr) sequence-dependent endoplasmic reticulum-associated 
protein degradation (ERAD) mechanism was established to decrease cellular levels of Erg9p without 
relying on inducers, repressors or specific repressing conditions. This improved nerolidol titre by 86 % 
to ~100 mg L
-1
. In this strain, squalene levels were similar to the wild-type control strain, and 
downstream ergosterol levels were slightly decreased relative to the control, indicating redirection of 
carbon away from sterols and towards sesquiterpene production. There was no negative effect on cell 
growth under these conditions. Protein degradation is an efficient mechanism to control carbon 
allocation at flux-competing nodes in metabolic engineering applications. This study demonstrates 
that an engineered ERAD mechanism can be used to balance flux competition between the 
endogenous sterol pathway and an introduced bio-product pathways at the FPP node. The approach of 
protein degradation in general might be more widely applied to improve metabolic engineering 
outcomes.   
Keywords: sesquiterpene, trans-nerolidol, metabolic engineering, Saccharomyces cerevisiae, 
endoplasmic reticulum-associated protein degradation (ERAD)  
 
1. Introduction 
Sesquiterpenes are 15-carbon isoprenoid compounds with a wide variety of industrial applications, 
including as fragrances and flavours; and as active molecules in pharmaceuticals, traditional herbs, 
and personal care products. If cost-competitive production can be achieved, they may also be useful as 
alternative fuels due to their high energy content. It is commonly uneconomical to produce bulk 
amounts of sesquiterpenes from natural (usually plant) sources or via semi/total chemical synthesis. 
Consequently, microbial fermentation from sugars using microbial cell factories is being pursued as a 
competitive approach for their bulk production (Ajikumar et al., 2010; Scalcinati et al., 2012b; Shiba 
et al., 2007; Vickers et al., 2015a).  
Sesquiterpenes are synthesized biologically from the common precursor farnesyl pyrophosphate (FPP) 
by specific sesquiterpene synthases. FPP is produced by condensation of the universal isoprenoid 
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backbone molecules, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP; 
Fig. 1). In S. cerevisiae, IPP and DMAPP are synthesized via the mevalonate (MVA) pathway from 
acetyl-CoA, with consumption of NADPH and ATP. The MVA pathway is naturally tightly regulated 
at transcriptional and post-transcriptional levels (Goldstein and Brown, 1990; Kuzuyama, 2002; 
Miziorko, 2011), limiting the overall metabolic flux for sesquiterpene production. In order to increase 
availability of FPP in the presence of a heterologous sesquiterpene synthase, the entire MVA pathway 
as well as FPP synthase are typically overexpressed. This strategy is used both in yeast and in E. coli, 
the latter of which uses the alternative methylerythritol phosphate pathway for native isoprenoid 
production (Bongers et al., 2015; Ignea et al., 2011; Tsuruta et al., 2009; Yoon et al., 2009).   
 
Fig. 1: The engineered mevalonate pathway and relevant downstream pathways, including 
endogenous genes: ERG10, acetoacetyl-CoA thiolase; ERG13, 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) synthase; tHMG1, truncated HMG-CoA reductase; ERG12, mevalonate 
kinase; ERG8, phosphomevalonate kinase; MVD1, mevalonate pyrophosphate decarboxylase; 
IDI1, isopentenyl diphosphate:dimethylallyl diphosphate isomerase; ERG20, farnesyl 
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pyrophosphate synthetase; ERG9, squalene synthase; ERG1, squalene epoxidase; and 
exogenous genes: EfmvaS, Enterococcus faecalis HMG-CoA synthase; EfmvaE, Enterococcus 
faecalis acetoacetyl-CoA thiolase/HMG-CoA reductase; AcNES1, Actinidia chinensis tran-
nerolidol synthase.  
In addition to the low capacity for prenyl phosphate (IPP/DMAPP/FPP) synthesis, non-productive 
consumption of FPP for sterol synthesis is a limitation for heterogeneous sesquiterpene production. 
Sterol synthesis from FPP is initiated by the branch-point enzyme squalene synthase, which 
condenses two molecules of FPP to squalene. Yeast strains with an enhanced MVA pathway exhibit 
dramatically elevated levels of squalene and sterols (Liu et al., 2013; Polakowski et al., 1998). It is not 
feasible to knock out squalene synthase (erg9) to decrease competition for production of novel 
sesquiterpenes, because sterols are essential cell components; erg9 dysfunction causes ergosterol 
auxotrophy. Conditional down-regulation of ERG9 at the transcriptional level has therefore been used 
to constrain squalene/sterol synthesis and increase heterogeneous sesquiterpene production. This has 
been achieved by replacing the native ERG9 promoter on the genome with various repressible 
promoters: MET3 (repressed upon addition of methionine to the medium), CRT3 (repressed on high-
concentration copper) or HXT1 (induced by high glucose and reduced under low glucose; 
transcription decreases after the exponential phase of batch cultivation) (Asadollahi et al., 2008; 
Paddon et al., 2013; Scalcinati et al., 2012a; Scalcinati et al., 2012b; Xie et al., 2014). However, these 
strategies require strict fermentation conditions and/or addition of repressors to achieve regulation, 
conditions that can increase the complexity and/or cost in industrial processes.  
Protein concentration is dynamically regulated in the cell by modulating the rates of transcription, 
RNA degradation, translation and/or protein degradation (Babiskin and Smolke, 2011; Jungbluth et al., 
2010; Raina and Crews, 2010; Sekar et al., 2016). In metabolic engineering, specific protein levels are 
typically controlled through transcription (at the promoter level); control mechanisms at other levels, 
especially at the protein level, have not been well exploited in yeast. Protein degradation is a natural 
mechansim widely used in many cellular/metabolic regulation processes, including  cell cycling 
(Sandoval et al., 2013) and sterol homeostasis (Christiano et al., 2014; Foresti et al., 2013; Meusser et 
al., 2005). In S. cerevisiae, the squalene-consuming enzyme squalene epoxidase (Erg1p; Fig. 1) has a 
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short half-life (60-80 min) due to protein degradation, whereas squalene synthase (Erg9p) is more 
stable, with a half life of 10 hours (Christiano et al., 2014; Foresti et al., 2013; Ruckenstuhl et al., 
2007). The short half-life of Erg1p provides a mechanism for the cell to rapidly shut down squalene 
consumption when high flux is not required for downstream synthesis (Foresti et al., 2013). 
Conversely, the stability of squalene synthase, presumably coupled with its ability to compete 
effectively with introduced sesquiterpene synthases, results in squalene accumulation in the absence 
of downstream consumption or when upstream flux is high (Liu et al., 2013; Polakowski et al., 1998). 
The stability of squalene synthase also means that the squalene synthase node is less sensitive to 
down-regulation using transcriptional approaches (Yuan and Ching, 2015), because a decrease in 
cellular squalene synthase levels after transcritpional inhibition depends on subsequent dilution of the 
Erg9p protein through cell division (Sekar et al., 2016). As a novel metabolic engineering strategy, 
protein destabilization might be able to effect a rapid reduction in absolute enzyme concentration 
(Jungbluth et al., 2010), thereby quickly diminishing competition at specific nodes.  
In the current study, trans-nerolidol was used to investigate a series of engineering strategies for 
improving sesquiterpene production in yeast. Trans-nerolidol is an important fragrance and flavour 
(Berger, 2007). Nerolidol also exhibits antiulcer (Klopell et al., 2007), antileishmanial (Arruda et al., 
2005) and insect repelling (Di Campli et al., 2012) activities. It is the main component of the essential 
oil and the biologically active component from fragrant rosewood (Dalbergia odorifera; Jiang Xiang 
in Chinese) heart wood; D. odorifera essential oil is used in Traditional Chinese Medicine for 
dispersing blood stasis in organs/tissues, and applied for treating coronary heart disease and angina 
pectoris (Li et al., 2014). As an intermediate, nerolidol is used to synthesize vitamins E and K1 
(Nissen et al., 1982), α-sinensal (a sweet orange aroma flavour, as in orange marmalade) (Ashurst, 
2012; Berger, 2007), and teprenone (geranylgeranylacetone; a drug used for the treatment of gastric 
ulcers) (Chen and Hu, 2004). In this work, core MVA pathway flux was first improved by over-
expression of native and heterologous pathway genes, leading to increased nerolidol production. 
Nerolidol production was then specifically improved by engineering a protein destabilization 
mechanism to reduce the FPP-consuming squalene synthase protein Erg9p, facilitating re-direction of 
carbon from squalene to nerolidol. 
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2. Materials and Methods 
2.1 Plasmid and Strain construction 
Plasmids used in this work are listed in Table 1 and strains are listed in Table 2. Primers used 
polymerase chain reaction (PCR) and PCR performed in this work are listed in Supplementary 
Materials: Table S1. Plasmid construction processes are listed in Supplementary Materials: Table 
S2. The genes encoding trans-nerolidol synthase (AcNES1; GenBank-KX064240) from Actinidia 
chinensis (Green et al., 2012), and 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) synthase 
(EfmvaS; GenBank-KX064238) and bi-functional acetoacetyl-CoA thiolase /HMG-CoA reductase 
(EfmvaE; GenBank-KX064239) from E. faecalis (Wilding et al., 2000) were synthesized by 
GenScript (Piscataway, NJ, USA) with codon optimization according to the codon bias of S. 
cerevisiae (Supplementary Materials: Table S3).  
Table 1: Plasmids used in this work 
 
  
Table 2: S. cerevisiae strains used in this work 
Plasmid Features Reference 
pILGFP89S Yeast integration plasmid; PTEF1-yEGFP (Peng et al., 2015) 
pILGFPJ1 Yeast integration plasmid; PTEF1-yEGFP-ERG9
Sig
 This work 
pILGFPU0 Yeast integration plasmid; PTEF1-yEGFP-ERG9
Sig
-
CLN2
PEST
 
This work 
pCEV-G1-Km E.coli/S. cerevisiae shuttle plasmid; 2μ, PPGK1-TCYC1 (Vickers et al., 
2013) 
pRS423 E.coli/S. cerevisiae shuttle plasmid; 2μ, HIS3 (Christianson et al., 
1992) 
pRS424 E.coli/S. cerevisiae shuttle plasmid; 2μ, TRP1 (Christianson et al., 
1992) 
pRS425 E.coli/S. cerevisiae shuttle plasmid; 2μ, LEU2 (Christianson et al., 
1992) 
pPMVAu5 pRS423: PSSA1-ERG10-TNAT1-PRPL4A-ERG13-TEFM1-
PRPL15A-tHMG1-TEBS1 
This work 
pPMVAu8 pRS423: PRPL4A-EfmvaS-TEFM1-PRPL15A-EfmvaE -TEBS1  This work 
pPMVAd3 pRS424: PRPL8B-ERG12-TNAT5-PSSB1-ERG8-TIDP1-PRPL3-
MVD1-TIDP1-PYEF3-IDI1-TRPL15A  
This work 
pJT1 pRS425: PTEF2-ERG20-TRPL3-PTEF1-AcNES1-TRPL41B This work 
pJT1R pRS425: PTEF2-ERG20-TRPL3 This work 
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Strain Genotype Resource/reference 
CEN.PK2-1C MATa ura3-52 trp1-289 leu2-3,112 his3Δ 1 (Entian and Kötter, 
1998) 
CEN.PK113-5D MATa ura3-52 (Entian and Kötter, 
1998) 
CEN.PK113-7D MATa (Entian and Kötter, 
1998) 
ILHA series strains:   
oURA3 CEN.PK2-1C derivative; URA3 This work 
Oref oURA3 derivative; [pRS423] [pRS424] [pRS425] This work 
N1 oURA3 derivative; [pRS423] [pRS424] [pJT1] This work 
N3 oURA3 derivative; [pPMVAu5] [pPMVAd3] [pJT1] This work 
N6 ILHA oURA3 derivative; [pPMVAu8] [pPMVAd3] 
[pJT1] 
This work 
O6 ILHA oURA3 derivative; [pPMVAu8] [pPMVAd3] 
[pJT1R] 
This work 
GH4 CEN.PK113-5D derivative; ura3(1,704 )::KlURA3 (Peng et al., 2015) 
G89S CEN.PK113-5D derivative; ura3(1, 704 )::KlURA3-
PTEF1-yEGFP 
(Peng et al., 2015) 
G89 CEN.PK113-5D derivative; ura3(1, 704)::KlURA3-
PTEF1-yEGFP-CLN2
PEST
 
(Peng et al., 2015) 
GJ1 CEN.PK113-5D derivative; ura3(1, 704)::KlURA3-
PTEF1-yEGFP-ERG9
Sig
 
This work 
GJ13GH GJ1 derivative; [pCEV-G1-Km(PPGK1-SEC63-mRFP1-
TCYC1)] 
This work 
GU0 CEN.PK113-5D derivative; ura3(1, 704)::KlURA3-
PTEF1-yEGFP-ERG9
Sig
-CLN2
PEST
 
This work 
oH5 oURA3 derivative;  ERG9(1333, 1335)::yEGFP-
CLN2
PEST
-TURA3-loxP-KlURA3-loxP  
This work 
oH5C oH5 derivative;  [pRS423] [pRS424]  [pRS425] This work 
oH6C oURA3 derivative;  ERG9(1333, 1335)::yEGFP-TURA3-
loxP-KlURA3-loxP [pRS423] [pRS424]  [pRS425] 
This work 
N6D oH5 derivative; [pPMVAu8] [pPMVAd3] [pJT1] This work 
 
Nerolidol-producing strains were constructed using S. cerevisiae CEN.PK2-1C (Table 2). The URA3 
gene was amplified from CEN.PK113-7D genomic DNA (Supplementary Materials: Table S1, #18) 
and was transformed to replace the dysfunctional ura3 gene in CEN.PK2-1c. To modify the Erg9p 
carboxyl-terminal (C-terminal) sequence, ERG9
C-terminal
-yEGFP-CLN2
PEST
-TURA3-LoxP-KlURA3-LoxP- 
TERG9 and ERG9
C-terminal
-yEGFP- TURA3-LoxP-KlURA3-LoxP- TERG9 were constructed through over-lap 
extension PCR (Supplementary Materials: Table S1, #19 & 20). The constructs included green 
fluorescence protein (GFP) with/without the G1 cyclin degradation domain (GLN2
PEST
), a selectable 
marker gene (URA3 from Kluyveromyces lactis), and two genomic integration sites (ERG9
C-terminal
 and 
TERG9) targeted to the C-terminal and terminator of ERG9. The resulting fragments were transformed 
into CEN.PK2-1c to generate two strains, ILHA oH5 (with CLN2
PEST
) and ILHA oH6 (without 
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CLN2
PEST
). Furthering strains were generated by co-transforming with the plasmids as indicated in 
Table 2. For nerolidol-producing strains, biological replication was achieved by storing at least three 
individual transformants from transformation plates in 20% glycerol stock at -80 C, as described 
previously (Bruschi et al., 2012). 
The strains GJ1 and GU0 expressing yEGFP-ERG9
Sig
 (GFP fused with Erg9p C-terminal 34 residues) 
and yEGFP-ERG9
ER
-CLN2
PEST
 respectively, were constructed by transforming SwaI-digested 
plasmids (pILGFPJ1 and pILGFPU0 respectively) into CEN.PK113-5D. The strain GJ13GH was 
generated by co-transforming the BamHI-digested pCEV-G1-Km and PCR fragments SEC63 and the 
red fluorescent protein (RFP) mRFP1 (http://parts.igem.org/Part:BBa_J61031) for the in-vivo plasmid 
assembly. 
2.2 Two-phase flask cultivation and sampling 
Nerolidol-producing strains were evaluated through two-phase flask cultivation (Vickers et al., 2015b). 
Synthetic minimal (SM) medium (containing 6.7 g L
-1
 yeast nitrogen base, YNB, Sigma-Aldrich 
#Y0626; pH 6.0) with 20 g L
-1
 glucose as the carbon source was used (SM-glucose). 100 mM 2-(N-
morpholino) ethanesulfonic acid (MES, Sigma-Aldrich#M8250) was used to buffer medium pH and 
the initial pH was adjusted to 6.0 by adding ammonium hydroxide. Strains were recovered from 
glycerol stocks by streaking on SM-glucose agar plates and pre-cultured in MES-buffered SM-
glucose medium to exponential phase (cell density OD600 between 1 and 4). Pre-cultured cells were 
collected by centrifugation and resuspend in fresh media before initiating two-phase cultivations. 
Two-phase flask cultivation was initiated by inoculating pre-cultured cells to OD600 = 0.2 in 25 ml 
MES-buffered SM-glucose medium in 250 ml flasks with solvent-resistant screw-caps (Vickers et al., 
2015b); 2 ml dodecane was added to extract nerolidol. Flask cultivation was performed at 30 C and 
200 rpm. For all cultivations, 1 ml culture was sampled at 0 hour; over the first 10 hr, 5 x 0.4 ml 
samples were taken to measure cell density; and at 72 hour, dodecane and culture were sampled for 
metabolite analysis (see below). For RNA extraction, 2 ml exponential-phase culture (OD600 = 1 to 1.5) 
was sampled and cells were collected and stored at -80 C. The cells from the final cultures (t = 72 
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hour) were washed twice with distilled water and aliquots were stored at -20 C for analysis of 
squalene and ergosterol. 
2.3 Confocal microscopy 
Yeast GJ13GH were grown in YPD broth (20 g L
-1
 peptone, 10 g L
-1
 yeast extract and 20 g L
-1
 
glucose) with 500 μg mL-1 G418 to exponential phase (OD600 = 1.0) and fixed in paraformaldehyde 
solution as described previously (Mazumder et al., 2013). Nucleic acid was dyed with 4',6-diamidino-
2-phenylindole (DAPI). Yeast cells were mounted on a poly-lysine bed on a glass slide. Fluorescent 
(DAPI, GFP and RFP) and transparent (T PMT) channels were photographed using an LSM 710 
confocal microscope (Zeiss) at the Queensland node of the Australian National Fabrication Facility. 
2.4 GFP fluorescence and degradation assay 
To monitor GFP fluorescence during the early exponential phase (OD600 = 0.4 to 0.8), cells were 
cultivated aerobically in 20 ml SM-glucose medium in a 100 ml flask. To monitor GFP fluorescence 
over the entire batch cultivation, cells were cultivated aerobically in MES-buffered 20 ml SM-glucose 
medium in 100 ml flasks. Samples were collected at indicated time points and GFP fluorescence in 
single cells was analysed immediately after sampling using a flow cytometer (BD Accuri
TM 
C6; BD 
Biosciences, USA). GFP fluorescence was excited by a 488 nm laser and monitored through a 530/20 
nm band-pass filter; 10,000 events were counted per sample. The GFP fluorescence signal was 
corrected according to the values of forward scatter and side scatter (Peng et al., 2015). GFP 
fluorescence level was expressed as the percentage relative to the background auto-fluorescence from 
a GFP-negative reference strain GH4 (empty vector integration strain). For the GFP degradation assay, 
cycloheximide was added into the culture to a final concentration of 50 mg L
-1
.  
2.5 Quantitation of mRNA level 
Total RNA was extracted using a yeast RiboPure™ RNA Purification Kit (Ambion #AM1926). After 
DNase treatment, 0.1 or 0.2 μg total RNA was used for first-strand cDNA synthesis in a 10 μl reaction 
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using ProtoScript® II Reverse Transcriptase (NEB #M0368). The diluted cDNA was used as the 
template for quantitative real-time (QRT) PCR (primers are listed in Supplementary Materials: 
Table S1, # 23 to # 38).  KAPA SYBR
®
 FAST qPCR Kit (KaPa Biosystems#KP-KK4601) and 
CFX96 Touch™ Real-Time PCR Detection System (BIO-RAD) were used in QRT-PCR. Yeast 
genomic or plasmid DNA was used for preparing the standard curve. Ct values were analysed using 
CFX Manager software (Bio-Rad Laboratories, QLD, Australia). The mRNA levels (N QRT-PCR 
copies pg
-1
 total RNA) were calculated by referring to the standard curve equations.  
2.6 Extraction of ergosterol and squalene 
In order to extract ergosterol and squalene, methanolic pyrogallol saponification (Adams and Parks, 
1968) was performed. The cell pellets were resuspended in 400 μl alkaline methanol (2 mol L-1 
potassium hydroxide) and 100 μl internal standard solution (400 μmol L-1 pyrene and 10 g L-1 
pyrogallol in methanol). Saponification was performed at 80 C in 2.2 mL screw-capped tubes for 1 
hour with mixing for 30 second every 15 minutes. Distilled water (500 μl) was added to dilute 
methanol saponification mixture and lipids were extracted with 1 ml hexane by regular vortex mixing 
over a period of 30 minutes. The upper 750 μl of the hexane phase was desiccated using a vacuum-
vent centrifuge, and the pellet was resuspended in 150 μl methanol:ethanol (1:1) solution containing 2 
g L
-1
 pyrogallol for HPLC analysis. Standards of ergosterol and squalene were prepared with 200 
μmol L-1 pyrene as internal standard, and pyrogallol was used as an anti-oxidant.   
2.7 Metabolite analysis 
Ergosterol, squalene and pyrene were analysed through reverse-phase chromatography using an 
Agilent 1200 HPLC system and a Gemini C18 column (150 x 4.6mm, 3µm, 110Å, Phenomenex PN: 
00F-4439-E0) with a guard column (SecurityGuard Gemini C18, Phenomenex PN: AJO-7597). 
Analytes were eluted isocratically at 1 mL min
-1
 with methanol at 35
 o
C. Analytes were monitored 
using a diode array detector (Agilent Technologies) at the following UV wavelengths: 200 nm (for 
squalene), 274 nm (for ergosterol) and 334 nm (for pyrene).  
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For trans-nerolidol analysis, dodecane samples were diluted 40-fold using hexane spiked with a β-
pinene internal standard. Diluted samples were analysed with gas chromatography-mass spectrometry 
using an Agilent 7890A GC system at Metabolomics Australia (Queensland Node). Samples (3 μL) 
were injected in split mode (ratio 1:30) at 250 C; analytes were separated on a FactorFour VF-5ms 
GC column (30m*0.25um*0.25um+10m EZ-guard; Agilent Technologies, PN: CP9013) with 1 mL 
min
-1
 helium flow and the following over temperature gradient program: 50 C for 2 min, +15 C min-
1
 to 200 C, 200 C for 3 min, +40 C min-1 to 325 C, 325 C for 0 min. Analytes were ionized and 
fragmented  using electron impact (EI) ionization source and detected by mass spectrometry  using a 
mass selective detector (MSD; Agilent Technologies#5975C).  
A novel HPLC method was developed to analyse geraniol, linalool, trans,trans-farnesol, trans-
nerolidol, geranylgeraniol, and geranyllinalool. Dodecane samples from fermentations were diluted in 
a 40-fold volume of ethanol. These samples (20μl) were analysed using an Agilent 1200 HPLC 
system with a Zorbax Extend C18 column (4.6 x 150 mm, 3.5 µm, Agilent PN: 763953-902) and a 
guard column (SecurityGuard Gemini C18, Phenomenex PN: AJO-7597). Analytes were eluted at 35 
o
C at 0.9 ml min
-1
 using a mixture of solvent A (high purity water,18.2 kΩ) and solvent B (45% 
acetonitrile, 45% methanol and 10% water), with a linear gradient of 5-100% solvent B from 0-24 
min, then 100% from 24-30 min, and finally 5% from 30.1-35 min. Analytes of interest were 
monitored using a diode array detector (Agilent DAD SL, G1315C) at 202 nm wavelength. Spectral 
scans were also performed on each of the compounds from 190-400 nm in steps of 2 nm to confirm 
their identity and purity.  
The standards of geraniol (98% purity; Sigma-Aldrich # 163333), linalool (97% purity; Sigma-
Aldrich # L2602), trans,trans-farnesol (96% purity; Sigma-Aldrich # 277541), trans-nerolidol (93.7% 
purity; Sigma-Aldrich #04610590), geranylgeraniol (85% purity; Sigma-Aldrich # G3278), and 
geranyllinalool (95% purity; Sigma-Aldrich # 48809),  were used to prepare the standard curve for 
quantification. 
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3. Results and Discussion 
To optimize heterologous sesquiterpene production in yeast, it is necessary to increase metabolic flux 
flowing through the MVA pathway, and to redirect flux from competing native isoprenoid production 
towards the desired end product (Asadollahi et al., 2008; Paddon et al., 2013; Tsuruta et al., 2009; 
Vickers et al., 2015a; Yoon et al., 2009). In metabolic engineering, transcriptional regulation is 
commonly employed to control enzyme levels (and consequently, metabolic flux) in desired pathways. 
Transcriptional outputs can be tuned by choosing promoters with different strength and/or expression 
patterns, or dynamically regulated by applying synthetic molecular circuits (Peng et al., 2015; 
Williams et al., 2015a; Williams et al., 2015b; Xie et al., 2014). Here, we examined a novel approach 
to modulate metabolic flux through destabilisation of a competing enzyme at a key node. In order to 
provide an industrially-relevant comparison between engineered strains intended for cheap industrial 
processes  (Hahn-Hägerdal et al., 2005), all strains were evaluated on synthetic minimal mineral 
medium (without any amino acid supplementation) with 20 g L
-1
 glucose as the carbon source. Genes 
for flux modification were expressed from plasmids, with the exception of the Erg9p tagging, which 
was done by editing the chromosomal Erg9 gene. 
3.1 Increasing trans-nerolidol production by enhancing the MVA pathway 
The production of sesquiterpenes in yeast is primarily limited by the weak synthetic capacity of the 
native MVA pathway (Vickers et al., 2015a). Initial strain engineering therefore focussed on 
increasing flux through the MVA pathway by overexpression of pathway genes (Fig. 1; Fig. 2a). FPP 
synthase (ERG20) was first introduced to improve flux to FPP, in conjunction with nerolidol synthase 
(AcNES1) from kiwifruit (A. chinensis) to catalyse nerolidol production. Strain N1, harbouring the 
nerolidol synthesis plasmid pJT1 (Fig. 2a; containing ERG20 under the control of the TEF2 promoter 
and the codon-opitmized AcNES1 under the control of TEF1 promoter) successfully produced 
nerolidol, but at low titres of only ~5 mg L
-1
 (Fig. 2b). No nerolidol was detected from the reference 
strain (Fig. 2b; strain Oref, harbouring empty plasmid vectors).  
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Fig. 2: Characterisation of nerolidol-producing strains: (a) schematic of over-expression 
cassettes on plasmids pJT1, pPMVAu5 (yeast upper MVA pathway genes; yMVA
upper
), 
pPMVAu8 (E. faecalis upper MVA pathway genes; EfMVA
upper
), and pPMVAd3 (yeast lower 
MVA pathway genes; yMVA
lower
) and the endoplasmic reticulum-associated protein 
degradation model for squalene synthase Erg9p destabilization: yEGFP, yeast enhanced green 
florescence protein; Cln2pPEST, PEST sequence (rich in Pro, Glu/Asp, Ser, and Thr) from the 
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G1 cyclin Cln2p, which leads protein degradation; (b) nerolidol titres at 72 hour, quantified 
through GC method (except that in O6, nerolidol was analysed through HPLC method and 
below the limit of quantification); (c) maximum specific growth rates (μmax) during the 
exponential phase; (d) growth curves over the batch cultivation; (e) titres of farnesol and 
geranylgeraniol at 72 hour, quantified through HPLC method; (f) mRNA levels during the 
exponential phase (OD600 = 1.0 to 1.5) for strains Oref, N3 and N6: the difference of mRNA 
levels of reference genes ACT1 and PDA1 is not significant (two-tailed t-test p > 0.1). Mean 
values ± standard deviations are shown (N ≥ 3). Two-tailed Welch's t-test was used for 
statistical analysis: n (not significant), p > 0.1; s (significant), p < 0.05. N.D., not detected.  
Augmentation of the MVA pathway was tested next. Comparative studies in E. coli have examined 
relative efficiency of MVA pathway genes from different species; in this system, the pathway is 
commonly divided into expression modules on either side of the core intermediate mevalonate, 
resulting in an “upper” part and a “lower” part (Fig. 1). The upper MVA pathway, especially the 
reaction catalysed by HMG-CoA reductase, is regarded as the main flux bottleneck (Paddon and 
Keasling, 2014). A truncated version of HMG-CoA reductase (tHMG1) lacking the membrane-
binding domain is used to avoid degradation-mediated feedback regulation at that node (Polakowski 
et al., 1998; Shimada et al., 1998). The E. coli studies have demonstrated that the “upper” module 
genes from E. faecalis are superior to S. cerevisiae genes, whereas “lower” module genes from S. 
cerevisiae and Streptococcus pneumoniae operate at similar efficiency, and are more efficient than the 
genes from E. faecalis, Staphylococcus aureus and Streptococcus pyogenes genes (Tsuruta et al., 2009; 
Yoon et al., 2009).  Several modules were examined to test if augmentation of the “upper” MVA 
module in yeast is more efficient using genes from E. faecalis as opposed to the equivalent yeast 
genes.  
A yeast “upper” module plasmid, pPMVAu5 (including yeast genes ERG10, ERG13 and tHMG1) and 
an E. faecalis upper MVA module plasmid, pPMVAu8 (including the codon-optimized E. faecalis 
genes EfmvaS and EfmvaE, the latter being a bi-functional acetoacetyl-CoA thiolase/HMG-CoA 
reductase) were first constructed (Fig. 2a). These modules were coupled with a “lower” MVA module 
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plasmid, pPMVAd3 (yeast ERG12, ERG8, MVD1 and IDI1) and the nerolidol synthesis plasmid pJT1 
(Fig. 2a).   
Augmentation of the core MVA pathway by over-expression of the native yeast genes increased 
nerolidol titre by 3.5-fold, to ~17.5 mg L
-1
 (Fig. 2b, strain N3 compared to strain N1). Heterologous 
expression of the E. faecalis “upper” MVA module increased nerolidol titre by a further ~3-fold, to 56 
mg L
-1
 (Fig. 2b, strain N6 compared to strain N3).  This demonstrates that in yeast, as in E. coli 
(Yoon et al., 2009), the E. faecalis genes are more effective than the yeast genes. However, both 
MVA pathway-supplemented strains exhibited decreased maximum specific growth rate (μmax) 
compared to strain N1 (Fig. 2c-d;  p<0.01). Compared to strain N1 (μmax = 0.3), strain N3 grew ~30 % 
more slowly (0.22 h
-1
), and strain N6 grew at about half the rate (0.14 h
-1
). These data confirm that 
supplementation of the MVA pathway improves accumulation of end products; however, they also 
demonstrate that pathway over-expression has a negative effect on growth rate.  
Native terpene synthases have not been found in S. cerevisiae; despite this, yeast can produce terpene 
alcohols (notably farnesol and some nerolidol), and production increases dramatically when FPP 
pools are increased by either over-expression of a truncated HMG-CoA reductase and/or deletion of 
squalene synthase (Carrau et al., 2005; Grabowska et al., 1998; Karst and Lacroute, 1977; McNeil, 
2008; McNeil et al., 2012; Zhuang, 2013). Proposed mechanisms for native terpenoid production 
include activity of FPP synthase, which can catalyse solvolysis of GPP to produce geraniol and FPP to 
produce nerolidol and farnesol (Poulter and Rilling, 1976; Saito and Rilling, 1979); non-specific 
phosphatase/pyrophosphatase activity (Chambon et al., 1990); and non-enzymatic hydrolysis (McNeil, 
2008). Non-enzymatic hydrolysis has been shown to be a major mechanism, and adjusting the 
medium pH to titrate farnesol:nerolidol ratios can yield nerolidol titres of up to 50 mg/L (McNeil, 
2008; McNeil et al., 2012). In squalene synthase knock-out strains with enhanced uptake of 
exogenous sterols and tHMGR over-expression, farnesol can accumulate up to 140 mg L
-1
 in 10-day 
cultivation on 20 g L
-1
 glucose  (Zhuang, 2013). Over-expression of a strawberry (Fragaria × 
ananassa) NES1 (FaNES1) effectively converted this farnesol to nerolidol (Zhuang, 2013). In some 
cases, native conversion of accumulated FPP to farnesol can outcompete a heterologously-expressed 
terpene synthase (Takahashi et al., 2007).  
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We therefore examined terpene alcohol production in the engineered strains (Supplementary 
Materials: Fig. S1). AcNES1 is known to have additional linalool/geranyllinalool synthase activities 
(Green et al., 2012); however, geraniol, linalool, farnesol, and geranyllinalool, were all below the 
limit of dectection in strain N6 (Supplementary Materials: Fig. S1). Conversely, a geranylgeraniol 
peak was detected (Supplementary Materials: Fig. S1). To examine this phenomenon more closely, 
a control strain overexpressing the MVA pathway genes and FPP synthase (plasmids pPMVAu8, 
pPMVAd3, and pJT1R) but without the AcNES1 gene, was made (strain O6). Strain O6 produced 
significantly lower geranylgeraniol (~0.7 mg L
-1
), compared to strain N6 (~9 g L
-1
; Fig. 2e). This 
indicates that geranylgeraniol can be produced in the absence of the nerolidol synthase, but that the 
nerolidol synthase also has geranylgeraniol synthase activity. This is surprising considering that 
exactly the same protein sequence was used as in the previous study, where linalool and 
geranyllinalool, but not  geranylgeraniol, were reported (Green et al., 2012). We presume that 
differences in in vitro conditions used previously, compared to our in vivo experiment, are responsible 
for this discrepancy. 
No trans-nerolidol was observed in strain O6, confirming that trans-nerolidol production is the result 
of AcNES1 activity. Instead, trans, trans-farnesol was detected in strain O6 (Supplementary 
Materials: Fig. S1) with a titre of ~11.7 mg L
-1
 (Fig. 2e). This is consistent with previous reports 
describing production of farnesol in strains over-expressing the mevalonate pathway with or without a 
sesquiterpene synthase (Muramatsu et al., 2009; Scalcinati et al., 2012a; Song, 2003). This activity is 
attributed to the presense of endogeneous phosphatase(s) (Farhi et al., 2011; Scalcinati et al., 2012a) 
The improved performance of the E. faecalis genes (strain N6) might be due to either higher catalytic 
efficiency of the enzymes encoded by EfmvaS and EfmvaE relative to the cognate yeast genes 
(ERG10/ERG13 and tHMG1, respectively), higher transcription/translation rate, or higher 
protein/mRNA stability. To examine relative transcript levels, the mRNA levels for genes involved in 
nerolidol production were analysed during exponential phase using QRT-PCR (Fig. 2f). Data are 
presented in log scale to facilitate direct comparisons. Transcripts for control genes actin (ACT1) and 
pyruvate dehydrogenase (PDA1) were similar (two-tailed t-test p > 0.1) in all strains in the 
exponential phase. The fold-changes (compared to the reference strain Oref) for the over-expressed 
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lower MVA pathway genes were similar in strains N3 (over-expressing yeast upper and lower MVA 
modules) and N6 (over-expressing E. faecalis upper and yeast lower MVA modules) - as expected, 
considering the same expression plasmids was used in both strains. 
For the “upper” MVA pathway genes, the transcript levels in strain N3 were increased by 10-fold for 
ERG10 and 5-fold for ERG13 and HMG1 relative to in the reference strain Oref. However, the 
observed transcript levels for the E. faecalis genes in strain N6 were significantly higher than those of 
the over-expressed yeast upper MVA module genes in strain N3: transcription levels of EfmvaS and 
EfmvaE in strain N6 were respectively 17-fold and 24-fold higher than the levels of genes ERG13 and 
HMG1 in strain N3. Although the constructs were controlled by the same promoter/terminator 
systems for both the yeast and E. faecalis modules (Fig. 2a), differences in mRNA levels may be due 
to stability of different transcripts (especially considering that the E. faecalis genes are not native 
genes while the yeast genes are native), or to idiosyncratic characteristics of the ORFs/constructs and 
their compatibility with specific promoters and terminators (Carquet et al., 2015; Yamanishi et al., 
2013).  Regardless of the mechanism, these data demonstrate that expression of the yeast genes is 
limited at the RNA level relative to the E. faecalis genes. This presumably results in improved 
pathway flux thus contributing to the improved nerolidol titre in the E. faecalis module strain, and 
also confirms that the upper part of the pathway is rate-limiting in this system.  
Despite our findings here, it has been previously been shown that the yeast HMG-CoA synthase 
(Erg13p) has higher catalytic efficiency than E. faecalis enzyme (EfmvaS) (Middleton, 1972; Skaff et 
al., 2012; Vannice et al., 2013). This suggests that the improved catalytic efficiency is not able to 
overcome the penalty conferred by decreased transcriptional efficiency. The kinetic parameters for 
yeast HMG-CoA reductase are not available. 
3.2 Minimising competition for FPP by destabilising squalene synthase  
Controlling carbon flux around FPP, the flux competing node, is required to improve accumulation of 
the desired sesquiterpenes. For metabolic engineering applications, transcription/RNA-level 
engineering has been used to regulate the flux-competing nodes, e.g., selecting a weaker promoter 
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(Scalcinati et al., 2012a) or applying RNA interference (Williams et al., 2015a). To direct more FPP 
toward sesquiterpene production, transcription of the native squalene synthase gene (ERG9) is 
commonly decreased by replacing the native promoter with a weaker promoter or a promoter that can 
be specifically down-regulated (Asadollahi et al., 2008; Paddon et al., 2013; Scalcinati et al., 2012a; 
Scalcinati et al., 2012b; Xie et al., 2014). Here we investigated a novel alternative strategy to regulate 
the level of Erg9p: a protein degradation mechanism to decrease protein half-life. 
3.2.1 The C-terminal of Erg9p is a  signal peptide targeting the endoplasmic reticulum and lipid 
droplets 
Human squalene synthase was shown to be bound to the endoplasmic reticulum (ER) membrane 
through C-terminal residues (Thompson et al., 1998). Consistent with this, the TMHMM Server 
online tool (Krogh et al., 2001) predicted that Erg9p has a C-terminal transmembrane domain with the 
N-terminal residues lying in the non-cytosol side of the membrane and C-terminal residues located 
across the membrane and in the cell cytosol (Fig. 3a). To test if the C-terminal residues could direct 
localisation to the ER membrane, the C-terminal 34 residues of Erg9p were attached to the C-terminal 
of yeast enhanced green fluorescent protein (yEGFP), and the fusion was expressed in yeast. 
Fluorescent microscopy showed that GFP was located in the perinuclear/peripheral organelles, a 
region recognised as the ER (Feldheim et al., 1992). Consistent with this, the GFP flouorescence in 
this region overlapped with red fluorescence from RFP-tagged Sec63p (Fig. 3b) , a protein known to 
localise to the ER (Feldheim et al., 1992). In addition to the ER, GFP signal was also observed in 
optically bright regions connecting to the ER (Fig. 3b; differential interference contrast imaging). 
These regions have been reported as lipid droplets (LDs) (Bouchez et al., 2015; Wolinski et al., 2011). 
Consistent with this localisation pattern, several other enzymes from ergosterol synthetic pathway, 
including Erg1p, Erg7p, and Erg27p, are also co-located in ER and LDs (Goodman, 2009; Leber et al., 
1998). As observed previously (Llopis et al., 1998; Mateus and Avery, 2000), un-tagged GFP is 
located in both cytosol and nucleus (Supplementary Materials: Fig. S2).  These data indicate that 
the C-terminal transmembrane domain of Erg9p function as an signal peptide targeting to ER and LDs.   
 
19 
 
 
Fig.3: Modification of the C-terminal of squalene synthase (Erg9p): (a) Erg9p transmembrane 
domain prediction via TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/); (b) 
imaging of GJ13GH cells expressing GFP labelled with the C-terminal 34 residues of Erg9p 
(ERG9
Sig
) and Sec63p-mRFP1; (c) GFP fluorescence levels in the strains G89S (expressing 
yEGFP), G89 (expressing yEGFP- CLN2
PEST
), GJ1(expressing yEGFP-ERG9
Sig
) and GU0 
(expressing yEGFP-ERG9
Sig
-CLN2
PEST
); (d) GFP degradation analysis after adding 
cycloheximide; (e) GFP fluorescence levels in strains with Erg9p C-terminal labelled with 
yEGFP- Cln2p
PEST
 (oH5C) or yEGFP (oH6C) over the whole batch cultivation. Mean values ± 
standard deviations are shown (N = 3). 
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3.2.2 Engineering CLN2PEST sequence-dependent degradation of  ER-associated protein with the 
Erg9p signal peptide 
In order to reasonably minimize Erg9p level, we exploited a post-transcriptional regulation strategy—
increasing protein degradation rate of Erg9p. Cytosolic proteins can be degraded through either N-
terminal or C-terminal destabilization peptides (Jungbluth et al., 2010; Varshavsky, 1996).  ER-
associated protein degradation (ERAD) is an important cellular pathway that targets misfolded ER 
proteins for degradation. The pathway includes mechanisms for targeting protein substrates,  
retrotranslocating the substrate to cytosol, ubiquitination at specific residues, and finally degradation 
via proteasomes (Lemus and Goder, 2014; Meusser et al., 2005). The Erg9p transmembrane peptide 
has histidine and arginine residues at the carboxyl end of the transmembrane, indicating that this end 
of the peptide is located in the cytosol (the “positive-inside rule”) (Goder et al., 2004; Krogh et al., 
2001). C-terminal ER-associated degradation was therefore identified as a potential degradation 
strategy. Several cytosol-side sequences rich in Pro, Glu (and Asp), Ser, and Thr amino acids (known 
as PEST seqeunces) have been shown to be responsible for the degradation of ER-located enzymes 
(Arteaga et al., 2006; Kato et al., 2006). To exploit this process for engineering Erg9p degradation, we 
labeled the cytosolic end of the Erg9p transmembrane domain with the G1 cyclin PEST sequence 
(CLN2
PEST
). The yeast G1 cyclin protein is very unstable, a characteristic that is partially determined 
by C-terminal PEST motif; and the G1 cyclin PEST sequence is sufficient to destabilise heterologous 
cytosolic proteins (Mateus and Avery, 2000; Salama et al., 1994).  
We first tested the PEST sequence-dependent ERAD model using ER-localized yEGFP. yEGFP 
constructs with or without the ERG9 ER signal peptide (ERG9
Sig
) and/or CLN2
PEST
 were expressed 
under the control of the TEF1 promoter. ERG9
Sig
 decreased GFP fluorescence by 33% (Fig. 3c), but 
did not affect GFP half-life: both the yEGFP construct strain and the yEGFP-ERG9
Sig
 construct strain 
demonstrated very stable GFP activity following addition of cycloheximide to prevent translation, 
with half-lives well in excess of the 60 min that the experiment was performed over (Fig. 3d). The 
CLN2
PEST
 fusion resulted in a significant decrease in GFP fluorescence in both the control yEGFP 
construct strain (10-fold) and in the yEGFP-ERG9
Sig
 construct strain (8-fold) (Fig. 3c). Presence of 
the CLN2
PEST
 decreased the GFP fluorescence half-life to just 10 min for the yEGFP construct strain 
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and to ~25 min for the yEGFP-ERG9
Sig
 construct strain (Fig. 3d). We presume that the GFP 
fluorescence behaves as a proxy for decreased protein half-life, indicating that the CLN2
PEST
 sequence 
can successfully destabilise the ER membrane-integrating proteins when fused to the cytosolic C-
terminal end, resulting in rapid protein degradation.  
To test the effect of a C-terminal CLN2
PEST
 peptide tag on Erg9p, both yEGFP and yEGFP-CLN2
PEST
 
were inserted at the 3′ end of the chromosomal ERG9 gene (Fig. 2a).  GFP fluorescence was used as a 
proxy for the relative abundance of the resulting fusion proteins (Chong et al., 2012; Newman et al., 
2006). Interestingly, the Erg9p-yEGFP strain exhibited a dramatic decrease in GFP fluorescence level 
in the post-exponential growth phase (Fig. 3e). This is in contrast to previous studies, which showed 
that β-galactosidase activity driven by the ERG9 promoter was stable throughout batch cultivation 
(Scalcinati et al., 2012a). In support of this, transcription of ERG9 decreased less than 15% relative to 
exponential phase transcription at 36 hours in the nerolidol-producing strains N6 (ERG9) and N6D 
(ERG9-yEGFP-CLN2
PEST
); in contrast, transcription of other tested genes decreased significantly 
more (ACT1, ERG1 and ERG2 by 50 %; and PDA1 by 30%; Supplementary Materials: Fig. S3). 
These results support natural regulation of squalene synthase at the post-transcriptional level 
(Devarenne et al., 2002; Otero et al., 2010). In addition, β-galactosidase is cytosolic, whereas the 
Erg9p-yEGFP protein is ER-associated. ER-associated proteins can be degraded through an 
autophagy process (Mochida et al., 2015; Schuck et al., 2014) which is induced during the diauxic 
shift (Galdieri et al., 2010). These two considerations may account for the post-transcriptional 
regulation on Erg9p observed in the current study. Supporting this idea,  the fluorescence pattern we 
observed is consistent with dynamic squalene accumulation observed in an MVA pathway-enhanced 
strain, which showed a decrease in squalene content in the ethanol growth phase relative to in the 
exponental growth phase (Mantzouridou and Tsimidou, 2010). These data suggest that squalene 
synthase is down-regulated as cell growth slows down during the diauxic shift.  
The presence of the CLN2
PEST
 tag (strain oH5C; ERG9-yEGFP-CLN2
PEST
) resulted in an ~4-fold 
decrease in GFP fluorescence in the exponential phase, and an ~2-fold decrease in the ethanol phase, 
compared to the control (strain oH6C; ERG9-yEGFP; Fig. 3e). Fluorescence levels still decreased 
over the diauxic shift, but by a relatively small amount compared to the sharp decrease seen in the 
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Erg9p-yEGFP strain. This suggests that the destabilisation approach successfully decreased fusion 
protein accumulation throughout the batch cultivation, and particularly during exponential phase. The 
modifications did not influence the cell growth (strain Oref in Fig. 2c; strains oH5C and OH6C in Fig. 
3e), suggesting that a decrease in Erg9p levels during the exponential phase can be well tolerated by 
the cell. This implies that squalene synthase levels might be naturally above the level required for 
normal cell growth during batch culture.  
3.2.3 Destabilisation of Erg9p increases nerolidol production  
To test for improved availability of FPP for nerolidol synthesis, plasmids harbouring the E. faecalis 
upper MVA pathway module, the yeast lower MVA pathway module, and ERG20 / NES1 were 
introduced into the Erg9p-destabilized background strain oH5, to produce strain N6D. Strain N6D 
exhibited an increase in nerolidol titre of 86 % compared to strain N6, to 105 mg L
-1
 (Fig. 2b). In 
contrast with strain N6, a farnesol peak was detected in strain N6D (Supplementary Materials: Fig. 
S1); the titre was ~23.5 mg L
-1
 (Fig. 2e). We presume that this is due to accumulation of intracellular 
FPP due to a reduction in squalene sythase activity. Similarly to strain N6, geranylgeraniol was also 
produced in strain N6D, at a titre of ~12 mg L
-1
.  
 
The MVA pathway genes and FPP synthase gene (pPMVAu8, pPMVAd3, and pJT1R) were 
introduced to the Erg9p-destabilized strain. The transformants grew on SM-glucose agar, but 
exhibited a growth deficiency characterised by instability and very slow growth rates in broth (data 
not shown). We presume this is due to over-accumulation of FPP,which can cause cellular toxicity 
(Dahl et al., 2013).  
The fold-increase achieved using Erg9p destabilization is comparable to the fold-increase observed 
for other terpene end-products when using the low-glucose-repressed HXT1 promoter to control 
ERG9 (Scalcinati et al., 2012a; Xie et al., 2014). The advantage for protein destablization strategy is 
that its regulation does not depend on having a low glucose concentration or addition of a repressor – 
as the HXT1/MET3/CRT3 promoters require. This is beneficial in an industrial process. Also, no 
difference in growth rate between strain N6 and strain N6D was observed (Fig. 2c-d: N6D vs. N6). 
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This suggets that destabilisation of Erg9p (and presumably concommitent increase in FPP availability) 
was successfully achieved, and can increase sesquitepene levels without further inhibiting growth in 
the presence of an over-expressed MVA pathway. 
3.4 Erg9p destabilisation redirects carbon from sterol synthesis towards heterologous 
sesquiterpene production  
Squalene accumulates at up to 1 % cell dry weight in strains with an enhanced MVA pathway (Liu et 
al., 2013; Polakowski et al., 1998). Successful redirection of carbon towards heterologous 
sesquiterpenes at the FPP node should result in decreased squalene accumulation coincident with 
increased sesquiterpene titres. We examined both squalene and downstream ergosterol accumulation 
(Fig. 4) to determine the effects of different engineering steps on sterol biosynthesis.   
 
Fig. 4: Intracellular squalene (a) and ergosterol (b) contents in nerolidol-producing yeast strains 
at 72 h. Mean values ± standard deviations are shown (N = 3). Two-tailed Welch's t-test was 
used for statistical analysis: n (not significant), relative to Oref, p > 0.1; s (significant), relative 
to Oref, p < 0.05. 
In the strain N3, harbouring the over-expressed yeast MVA pathway and exhibiting relativey low 
levels of nerolidol (Fig. 2b), the squalene and ergosterol levels did not change significantly relative to 
the reference strain Oref (Fig. 4). This suggests that pathway flux was not strongly increased 
compared to the wild type, and that any excess pathway flux overflowed to nerolidol or other sterol 
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intermediates. Heterologous expression of the the E. faecalis upper MVA module (strain N6) 
produced ~3-fold more nerolidol (Fig. 2b) and ~10-fold more squalene  (Fig. 4a), consistent with 
previous studies showing accumulation of squalene in pathway-engineered strains with high flux (Liu 
et al., 2013; Polakowski et al., 1998). Ergosterol levels were not significantly affected in this strain 
(Fig. 4b).  
Destabilisation of squalene synthase (strain N6D, harbouring the E. faecalis module and the 
destabilised Erg9) caused a significant decrease in squalene relative to strain N6, to levels similar to 
the reference strain Oref (Fig. 4a). Moreover, ergosterol pools were also affected, with levels 
decreasing by 35% compared strain N6 and 43% compared to strain Oref. This is consistent with 
decreased ergosterol levels observed in strains with transcriptional down-regulation of squalene 
synthase using the methionine-repressible MET3 promoter or the low-glucose-repressible HXT1 
promoter (Asadollahi et al., 2010; Scalcinati et al., 2012a). Raw mass balance calculations indicated 
the decreased squalene/ergosterol contents could contribute to ~30 mg L
-1
 increase in sesquiterpene 
(nerolidol + farnesol)
 
titre. Here, ~70 mg L
-1 
improvement in in N6D relative to N6 was observed, 
suggesting that other sterol intermediates may also be re-directed to nerolidol production in the 
destabilised strain. These data indicate that destabilization of Erg9p can redirect carbon at the FPP 
node away from squalene/sterol production and towards alternative sesquiterpene production in the 
presence of an enhanced MVA pathway. 
4. Summary and Conclusion 
In this study, we first improved MVA pathway flux by over-expression/heterologous expression of 
pathway genes. As in E. coli (Tsuruta et al., 2009; Yoon et al., 2009), the heterologous E. faecalis 
genes in the upstream module of the MVA pathway provided better pathway flux than the native yeast 
genes (Fig. 2b). We further demonstrated that improved transcript stability is likely a contributing 
factor to the higher efficiency of the E. faecalis genes (Fig. 2f). Further improvement of trans-
nerolidol production was achieved by regulating the flux-competing enzyme squalene synthase 
(Erg9p) via a novel engineered ERAD mechanism. We demonstrated that the C-terminal region of 
Erg9p behaved as a signal peptide partially targeting to ER membrane; then showed that fusing a 
25 
 
PEST sequence to the cytosolic ER-integration end of a protein can drive an ERAD response, 
significantly shortening protein half-life (Fig. 3). This protein destabilizing strategy was then applied 
to reduce squalene synthase level; this improved the trans-nerolidol production and also resulted in 
some farnesol production by redirecting carbon from sterol synthesis and into sesquiterpene synthesis 
(Fig. 2b & Fig. 4). In contrast to previous transcriptionally-mediated approaches to regulate squalene 
synthase (Asadollahi et al., 2008; Paddon et al., 2013; Scalcinati et al., 2012a; Scalcinati et al., 2012b; 
Xie et al., 2014), the destabilization strategy does not require either addition of repressors which may 
increase the cost of the bioprocess (in the case of repressible promoters), or appropriately repressing 
fermentation conditions (in the case of glucose-responsive promoter). Destabilisation of squalene 
synthase does not inhibit the maximum specific growth rate. Protein degradation is a novel 
mechanism to effectively control carbon allocation at flux-competing nodes in metabolic engineering 
applications. In future studies, titration of squalene synthase levels by modifying expression levels 
might improve carbon allocation balance, further improving heterologous sesquiterpene levels. 
Balancing the upstream pathway over-expression might also avoid growth inhibition in pathway over-
expression strains. 
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Highlights:  
 Squalene synthase was modulated by a protein degradation mechanism. 
 Squalene synthase C-terminal peptide is an ER-targeting transmembrane signal peptide. 
 A mechanism was engineered to degrade ER membrane-integrating protein. 
 Enterococcus mvaS and mvaE were used to improve sesquiterpene production in yeast. 
 Destabilizing squalene synthase redirects carbon flux to nerolidol production. 
